Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | No |
| Is net profit margin increasing? | Yes | No |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| 4Front Ventures Corp. |
| Evolus, Inc. |
| Tarsus Pharmaceuticals, Inc. |
| Bio Essence Corporation |
| Corcept Therapeutics Incorporated |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| FFNT.F | EOLS | TARS | BIOE | CORT | CNBX | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 71% | -949% | -34% | 70% | 22% | NA | ||
| Fiscal Year - 1 | -65% | NM | -70% | NA | 21% | 203% | ||
| Fiscal Year - 2 | -96% | -148% | -35% | 19% | 23% | -4289% | ||
| Fiscal Year - 3 | -103% | -1050% | -8% | 31% | 25% | NA | ||
| Fiscal Year - 4 | -287% | -5017% | NA | 42% | 24% | -90% | ||
| Fiscal Year - 5 | -35% | -110% | NA | 372% | 29% | 13% | ||
| Average | -86% | -1455% | -37% | 107% | 24% | -1041% | ||
| Median | -81% | -949% | -34% | 42% | 23% | -39% | ||
| Benchmarks | Ticker | |||||||
| 4Front Ventures Corp. | OTCPK:FFNT.F | |||||||
| Evolus, Inc. | NasdaqGM:EOLS | |||||||
| Tarsus Pharmaceuticals, Inc. | NasdaqGS:TARS | |||||||
| Bio Essence Corporation | OTCPK:BIOE | |||||||
| Corcept Therapeutics Incorporated | NasdaqCM:CORT | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | FFNT.F | EOLS | TARS | BIOE | CORT | CNBX | ||
| Latest Fiscal Year | Dec-23 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Aug-24 | ||
| LTM Period | Sep-24 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Feb-25 | ||
| Revenues | ||||||||
| Latest Twelve Months | 76 | 275 | 234 | 0 | 685 | 0 | ||
| Fiscal Year | 97 | 266 | 183 | 0 | 675 | 0 | ||
| Fiscal Year - 1 | 108 | 202 | 17 | NA | 482 | 0 | ||
| Fiscal Year - 2 | 105 | 149 | 26 | 1 | 402 | 0 | ||
| Fiscal Year - 3 | 58 | 100 | 57 | 1 | 366 | NA | ||
| Fiscal Year - 4 | 19 | 57 | NA | 1 | 354 | 0 | ||
| Fiscal Year - 5 | 4 | 35 | NA | 1 | 306 | 0 | ||
| Net Income | ||||||||
| Latest Twelve Months | (35) | (56) | (105) | (2) | 133 | (0) | ||
| Fiscal Year | (45) | (50) | (116) | (2) | 140 | (1) | ||
| Fiscal Year - 1 | (21) | (62) | (136) | (0) | 105 | (4) | ||
| Fiscal Year - 2 | (38) | (74) | (62) | (1) | 101 | (4) | ||
| Fiscal Year - 3 | (60) | (47) | (14) | (1) | 113 | (3) | ||
| Fiscal Year - 4 | (179) | (163) | (27) | (1) | 106 | (7) | ||
| Fiscal Year - 5 | (9) | (90) | (5) | (2) | 94 | 1 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 269 | 226 | 349 | 2 | 656 | 0 | ||
| Latest Fiscal Quarter | 278 | 213 | 501 | 0 | 846 | 0 | ||
| Fiscal Year | 264 | 233 | 377 | 0 | 841 | 0 | ||
| Fiscal Year - 1 | 345 | 189 | 265 | 3 | 622 | 0 | ||
| Fiscal Year - 2 | 256 | 178 | 228 | 2 | 583 | 1 | ||
| Fiscal Year - 3 | 205 | 257 | 179 | 2 | 424 | 3 | ||
| Fiscal Year - 4 | 203 | 209 | 172 | 2 | 572 | 2 | ||
| Fiscal Year - 5 | 60 | 240 | 58 | 2 | 412 | 15 | ||
| Fiscal Year - 6 | 14 | 172 | 2 | 1 | 312 | 3 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | (51) | 18 | 275 | (2) | 548 | (2) | ||
| Latest Fiscal Quarter | (49) | (7) | 342 | (3) | 683 | (3) | ||
| Fiscal Year | (52) | 6 | 225 | (3) | 680 | (2) | ||
| Fiscal Year - 1 | 28 | (21) | 197 | (2) | 507 | (2) | ||
| Fiscal Year - 2 | 37 | 18 | 193 | (3) | 502 | (2) | ||
| Fiscal Year - 3 | 42 | 82 | 167 | (2) | 376 | 2 | ||
| Fiscal Year - 4 | 75 | (73) | 166 | (2) | 523 | 2 | ||
| Fiscal Year - 5 | 50 | 79 | (6) | (1) | 371 | 15 | ||
| Fiscal Year - 6 | (0) | 84 | (1) | 0 | 276 | 3 | ||